Hi Tech Pharmacal
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Hi Tech Pharmacal's revenues will contract -1.9% and EPS will contract -48.1%.
The average estimate for revenue is $55.8 million. On the bottom line, the average EPS estimate is $0.56.
Last quarter, Hi Tech Pharmacal chalked up revenue of $52.0 million. GAAP reported sales were 7.4% lower than the prior-year quarter's $56.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.44. GAAP EPS of $0.44 for Q1 were 58% lower than the prior-year quarter's $1.05 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 48.7%, 1,040 basis points worse than the prior-year quarter. Operating margin was 16.3%, 1,980 basis points worse than the prior-year quarter. Net margin was 11.5%, 1,300 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $234.3 million. The average EPS estimate is $2.60.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 206 members out of 223 rating the stock outperform, and 17 members rating it underperform. Among 43 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 39 give Hi Tech Pharmacal a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hi Tech Pharmacal is outperform, with an average price target of $37.83.
- Add Hi Tech Pharmacal to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.